Mink Therapeutics Net Worth
Mink Therapeutics Net Worth Breakdown | INKT |
Mink Therapeutics Net Worth Analysis
Mink Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mink Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mink Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mink Therapeutics' net worth analysis. One common approach is to calculate Mink Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mink Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mink Therapeutics' net worth. This approach calculates the present value of Mink Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mink Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mink Therapeutics' net worth. This involves comparing Mink Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mink Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Mink Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mink Therapeutics' net worth research are outlined below:
| Mink Therapeutics had very high historical volatility over the last 90 days | |
| Mink Therapeutics has some characteristics of a very speculative penny stock | |
| Mink Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.46 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mink Therapeutics currently holds about 29.85 M in cash with (15.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.88. | |
| Mink Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 71.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Corvese Brian of 17967 shares of Mink Therapeutics at 0.99 subject to Rule 16b-3 |
Mink Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mink Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mink Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Mink Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mink Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mink Therapeutics backward and forwards among themselves. Mink Therapeutics' institutional investor refers to the entity that pools money to purchase Mink Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jane Street Group, Llc | 2023-12-31 | 18.4 K | Northern Trust Corp | 2024-03-31 | 11.1 K | Wells Fargo & Co | 2024-03-31 | 11 K | Tower Research Capital Llc | 2023-12-31 | 10.9 K | Ubs Group Ag | 2024-03-31 | 3.2 K | Bank Of America Corp | 2024-03-31 | 3.1 K | Qube Research & Technologies | 2024-03-31 | 1.9 K | Artal Group S A | 2023-12-31 | 1.9 K | California State Teachers Retirement Sys | 2024-03-31 | 1.5 K | Vanguard Group Inc | 2024-03-31 | 234.2 K | Longbow Finance Sa | 2024-03-31 | 166.7 K |
Follow Mink Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 39.17 M.Market Cap |
|
Project Mink Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.93) | (5.18) | |
| Return On Capital Employed | 3.35 | 3.51 | |
| Return On Assets | (4.93) | (5.18) | |
| Return On Equity | 1.24 | 1.18 |
When accessing Mink Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mink Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mink Therapeutics' profitability and make more informed investment decisions.
The data published in Mink Therapeutics' official financial statements typically reflect Mink Therapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Mink Therapeutics' quantitative information. For example, before you start analyzing numbers published by Mink accountants, it’s essential to understand Mink Therapeutics' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the imprecision that can be found in Mink Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mink Therapeutics. Check Mink Therapeutics' Beneish M Score to see the likelihood of Mink Therapeutics' management manipulating its earnings.
Evaluate Mink Therapeutics' management efficiency
Mink Therapeutics has return on total asset (ROA) of (1.101) % which means that it has lost $1.101 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.3898) %, meaning that it created substantial loss on money invested by shareholders. Mink Therapeutics' management efficiency ratios could be used to measure how well Mink Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 3.51 in 2024, whereas Return On Tangible Assets are likely to drop (5.18) in 2024. At this time, Mink Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 15.7 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 4.3 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.53) | (0.55) | |
| Tangible Book Value Per Share | (0.53) | (0.55) | |
| Enterprise Value Over EBITDA | (1.47) | (1.54) | |
| Price Book Value Ratio | (2.04) | (2.14) | |
| Enterprise Value Multiple | (1.47) | (1.54) | |
| Price Fair Value | (2.04) | (2.14) | |
| Enterprise Value | 33.4 M | 31.7 M |
The analysis of Mink Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Mink Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Mink Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Return On Equity (12.39) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mink Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mink Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mink Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mink Therapeutics time-series forecasting models is one of many Mink Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mink Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Mink Therapeutics Earnings per Share Projection vs Actual
Mink Therapeutics Corporate Management
| Kimberly Ha | Head Relations | Profile | |
| Joy Zhou | Vice CMC | Profile | |
| Marcus Dijk | Chief Officer | Profile | |
| Heather Boussios | General Officer | Profile | |
| Christine Klaskin | Treasurer | Profile |
Additional Tools for Mink Stock Analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.